|1||Active, not recruiting||
AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer
|2||Active, not recruiting||
Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer
† Study has passed its completion date and status has not been verified in more than two years.